Skip to main content
Erschienen in: Advances in Therapy 4/2015

01.04.2015 | Original Research

Does Defibrotide Induce a Delay to Polymorphonuclear Neutrophil Engraftment After Hematopoietic Stem Cell Transplantation? Observation in a Pediatric Population

verfasst von: Natalia Maximova, Antonio Pizzol, Nagua Giurici, Marilena Granzotto

Erschienen in: Advances in Therapy | Ausgabe 4/2015

Einloggen, um Zugang zu erhalten

Abstract

Introduction

In recent years, defibrotide (DFT) has emerged as a promising therapy for veno-occlusive disease (VOD). The aim of this study was to investigate whether DFT prophylaxis affects neutrophil engraftment in patients undergoing hematopoietic stem cell transplantation (HSCT).

Methods

A cohort of 44 consecutive pediatric patients who underwent HSCT was retrospectively analyzed to see the role of DFT on engraftment. Patients were assigned into two groups based on the use or non-use of prophylaxis with DFT.

Results

The mean time to engraftment was statistically different between the two groups for both polymorphonuclear neutrophils (PMN) and white blood cells.

Conclusion

Our study supports the hypothesis that prophylaxis with DFT for VOD leads to a delay to the engraftment of PMN in pediatric patients that underwent HSCT.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Pescador R, Capuzzi L, Mantovani M, Fulgenzi A, Ferrero ME. Defibrotide: properties and clinical use of an old/new drug. Vascul Pharmacol. 2013;59:1–10.CrossRefPubMed Pescador R, Capuzzi L, Mantovani M, Fulgenzi A, Ferrero ME. Defibrotide: properties and clinical use of an old/new drug. Vascul Pharmacol. 2013;59:1–10.CrossRefPubMed
2.
Zurück zum Zitat Richardson RG, Soiffer RJ, Antin JH, et al. Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial. Biol Blood Marrow Transplant. 2010;16:1005–17.CrossRefPubMedCentralPubMed Richardson RG, Soiffer RJ, Antin JH, et al. Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial. Biol Blood Marrow Transplant. 2010;16:1005–17.CrossRefPubMedCentralPubMed
3.
Zurück zum Zitat Scalia R, Pearlman S, Campbell B, Lefer AM. Time course of endothelial dysfunction and neutrophil adherence and infiltration during murine traumatic shock. Shock. 1996;6:177–82.CrossRefPubMed Scalia R, Pearlman S, Campbell B, Lefer AM. Time course of endothelial dysfunction and neutrophil adherence and infiltration during murine traumatic shock. Shock. 1996;6:177–82.CrossRefPubMed
4.
Zurück zum Zitat Ferraresso M, Rigotti P, Stepkowski SM, Chou TC, Kahan BD. Immunosuppressive effects of defibrotide. Transplantation. 1993;56:928–33.CrossRefPubMed Ferraresso M, Rigotti P, Stepkowski SM, Chou TC, Kahan BD. Immunosuppressive effects of defibrotide. Transplantation. 1993;56:928–33.CrossRefPubMed
5.
Zurück zum Zitat Fumagalli G, Sala C, Angelaccio E, Lombardo N, Clementi F. Thrombolytic activity of defibrotide: a morphometric evaluation in experimental venous thrombosis. Pharmacol Res. 1989;21:293–8.CrossRefPubMed Fumagalli G, Sala C, Angelaccio E, Lombardo N, Clementi F. Thrombolytic activity of defibrotide: a morphometric evaluation in experimental venous thrombosis. Pharmacol Res. 1989;21:293–8.CrossRefPubMed
6.
Zurück zum Zitat Bendtzen K. Interleukin 1, interleukin 6 and tumor necrosis factor in infection, inflammation and immunity. Immunol Lett. 1988;19:183–91.CrossRefPubMed Bendtzen K. Interleukin 1, interleukin 6 and tumor necrosis factor in infection, inflammation and immunity. Immunol Lett. 1988;19:183–91.CrossRefPubMed
7.
Zurück zum Zitat Dalmau SR, Freitas CS, Tabak DG. Interleukin-1 and tumor necrosis factor-alpha as radio- and chemoprotectors of bone marrow. Bone Marrow Transplant. 1993;12:551–63.PubMed Dalmau SR, Freitas CS, Tabak DG. Interleukin-1 and tumor necrosis factor-alpha as radio- and chemoprotectors of bone marrow. Bone Marrow Transplant. 1993;12:551–63.PubMed
8.
Zurück zum Zitat Neta R, Keller JR, Ali N, Blanchette F, Dubois CM. Contrasting mechanisms of the myeloprotective effects of interleukin-1 against ionizing radiation and cytotoxic 5-fluorouracil. Radiat Res. 1996;145:624–31.CrossRefPubMed Neta R, Keller JR, Ali N, Blanchette F, Dubois CM. Contrasting mechanisms of the myeloprotective effects of interleukin-1 against ionizing radiation and cytotoxic 5-fluorouracil. Radiat Res. 1996;145:624–31.CrossRefPubMed
9.
Zurück zum Zitat Schroder H. Defibrotide protects endothelial cells, but not L929 tumour cells, from tumour necrosis factor-alpha-mediated cytotoxicity. J Pharm Pharmacol. 1995;47:250–2.CrossRefPubMed Schroder H. Defibrotide protects endothelial cells, but not L929 tumour cells, from tumour necrosis factor-alpha-mediated cytotoxicity. J Pharm Pharmacol. 1995;47:250–2.CrossRefPubMed
10.
Zurück zum Zitat Hohlfeld T, Bucha E, Nowak G, Bruggener E, Strobach H, Schror K. Favourable effect of defibrotide in lipid A-induced shock in pigs. Circ Shock. 1992;38:122–9.PubMed Hohlfeld T, Bucha E, Nowak G, Bruggener E, Strobach H, Schror K. Favourable effect of defibrotide in lipid A-induced shock in pigs. Circ Shock. 1992;38:122–9.PubMed
11.
Zurück zum Zitat Maximova N, Ferrara G, Minute M, et al. Experience from a single paediatric transplant centre with identification of some protective and risk factors concerning the development of hepatic veno-occlusive disease in children after allogeneic hematopoietic stem cell transplant. Int J Hematol. 2014;99:766–72.CrossRefPubMed Maximova N, Ferrara G, Minute M, et al. Experience from a single paediatric transplant centre with identification of some protective and risk factors concerning the development of hepatic veno-occlusive disease in children after allogeneic hematopoietic stem cell transplant. Int J Hematol. 2014;99:766–72.CrossRefPubMed
Metadaten
Titel
Does Defibrotide Induce a Delay to Polymorphonuclear Neutrophil Engraftment After Hematopoietic Stem Cell Transplantation? Observation in a Pediatric Population
verfasst von
Natalia Maximova
Antonio Pizzol
Nagua Giurici
Marilena Granzotto
Publikationsdatum
01.04.2015
Verlag
Springer Healthcare
Erschienen in
Advances in Therapy / Ausgabe 4/2015
Print ISSN: 0741-238X
Elektronische ISSN: 1865-8652
DOI
https://doi.org/10.1007/s12325-015-0203-7

Weitere Artikel der Ausgabe 4/2015

Advances in Therapy 4/2015 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.